Recent Updates
Recently added Catalysts
LENZ Negative Sentiment Score: 20/100

LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm

Key Takeaway: LENZ Therapeutics, Inc. is being investigated by the Portnoy Law Firm for possible securities fraud after a significant drop in stock price. On December 12, 2025, the company's stock plummeted by 25.96% to $18.14 per share, largely due to adverse safety data regarding its VIZZ eye drop. Reports of a retinal tear linked to the product raised safety concerns, triggering a loss of investor confidence and highlighting the risks associated with the product. The law firm is seeking investors who wish to pursue claims related to these developments.

Market Sentiment Analysis

CONCERNS & RISKS

  • LENZ Therapeutics is under investigation for possible securities fraud.
  • The company's stock price fell 25.96% following concerns about safety data.
  • A severe ocular complication related to their VIZZ eye drop was disclosed.
  • The market has adjusted negatively due to risks affecting future adoption of their treatment.

Full Press Release Details

LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises LENZ Therapeutics, Inc., (“LENZ" or the "Company") (NASDAQ: LENZ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/lenz-therapeutics-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
LENZ’s stock price plummeted $6.36 per share, or 25.96%, to close at $18.14 per share on December 12, 2025, thereby injuring investors. This sharp market contraction was triggered by a December 12, 2025, emergence of safety data regarding the Company’s primary ophthalmic product. The primary driver of the valuation collapse was the public disclosure of a severe ocular complication documented within the Food and Drug Administration’s adverse event reporting systems.
Specifically, reports surfaced detailing a "case of retinal tear associated with LENZ’s VIZZ eye drop," a development that raised immediate concerns regarding the product's safety profile and potential regulatory scrutiny. The decline was further exacerbated as media outlets and analysts began circulating the news of this adverse event, highlighting the risks to the Company's commercial prospects. The revelation that a patient had suffered a significant structural injury to the eye following the use of VIZZ led to an immediate loss of investor confidence and a rapid erosion of shareholder value as the market adjusted to the heightened liability risks and the potential for a material decline in future adoption of the treatment.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
Attorney Advertising

Tags

Frequently Asked Questions

What is the investigation about LENZ Therapeutics?

The Portnoy Law Firm is investigating LENZ Therapeutics for possible securities fraud.

Why did LENZ's stock price drop significantly?

LENZ’s stock price fell 25.96% due to safety concerns regarding its VIZZ eye drop.

How can investors join the legal case against LENZ?

Investors can contact Lesley F. Portnoy or join via the Portnoy Law Firm’s website.

What triggered the decline in LENZ's market valuation?

The decline was triggered by reports of a serious eye injury related to VIZZ.

What does Portnoy Law Firm offer to investors?

The firm provides complimentary case evaluations to discuss options for recovery.

Last updated: Apr 23, 2026